0001209191-20-060591.txt : 20201125 0001209191-20-060591.hdr.sgml : 20201125 20201125190009 ACCESSION NUMBER: 0001209191-20-060591 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201123 FILED AS OF DATE: 20201125 DATE AS OF CHANGE: 20201125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Clague Laura CENTRAL INDEX KEY: 0001388773 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36257 FILM NUMBER: 201352408 MAIL ADDRESS: STREET 1: 370 PARK RANCH PLACE CITY: ESCONDIDO STATE: CA ZIP: 92025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Travere Therapeutics, Inc. CENTRAL INDEX KEY: 0001438533 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262383102 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 888-969-7879 MAIL ADDRESS: STREET 1: 3611 VALLEY CENTRE DR STREET 2: SUITE 300 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Retrophin, Inc. DATE OF NAME CHANGE: 20130220 FORMER COMPANY: FORMER CONFORMED NAME: Desert Gateway, Inc. DATE OF NAME CHANGE: 20080625 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-11-23 0 0001438533 Travere Therapeutics, Inc. RTRX 0001388773 Clague Laura C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DR., SUITE 300 SAN DIEGO CA 92130 0 1 0 0 Chief Financial Officer Common Stock 2020-11-23 4 A 0 7500 0.00 A 26973 D Common Stock 2020-11-24 4 S 0 3750 23.86 D 23223 D Common Stock 2020-11-25 4 S 0 3750 22.72 D 19473 D On May 17, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 23, 2020, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion. The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. /s/ Elizabeth E. Reed, Attorney-in-Fact 2020-11-25